Jane Street Group LLC Acquires New Holdings in Abrdn Life Sciences Investors (NYSE:HQL)

Jane Street Group LLC bought a new stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 22,098 shares of the company's stock, valued at approximately $290,000. Jane Street Group LLC owned 0.08% of Abrdn Life Sciences Investors as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. BankPlus Trust Department acquired a new position in shares of Abrdn Life Sciences Investors during the fourth quarter valued at $28,000. Steward Partners Investment Advisory LLC boosted its holdings in shares of Abrdn Life Sciences Investors by 379.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company's stock valued at $64,000 after acquiring an additional 3,847 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Abrdn Life Sciences Investors during the fourth quarter valued at approximately $154,000. Kapstone Financial Advisors LLC raised its holdings in Abrdn Life Sciences Investors by 11.0% during the fourth quarter. Kapstone Financial Advisors LLC now owns 13,123 shares of the company's stock worth $185,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Guggenheim Capital LLC bought a new position in Abrdn Life Sciences Investors during the 4th quarter valued at $211,000. 32.21% of the stock is owned by institutional investors.

Abrdn Life Sciences Investors Price Performance

Abrdn Life Sciences Investors stock traded up $0.02 during midday trading on Thursday, hitting $12.57. The company's stock had a trading volume of 62,397 shares, compared to its average volume of 126,460. The stock's 50-day moving average price is $12.13 and its 200-day moving average price is $13.13. Abrdn Life Sciences Investors has a 12 month low of $10.55 and a 12 month high of $15.90.

Abrdn Life Sciences Investors Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Thursday, May 22nd will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 13.68%. The ex-dividend date of this dividend is Thursday, May 22nd.

Insider Transactions at Abrdn Life Sciences Investors

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 32,922 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $13.01, for a total value of $428,315.22. Following the transaction, the insider now owns 3,240,630 shares in the company, valued at approximately $42,160,596.30. This represents a 1.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 210,080 shares of company stock valued at $2,565,065 over the last ninety days. Corporate insiders own 10.06% of the company's stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.